Nkarta, a preclinical biotech developing off-the-shelf cancer therapies based on natural killer cells, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company submitted an IND for its product NKX101 for the treatment of relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes (MDS) in May 2020.
The South San Francisco, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol NKTX. Nkarta filed confidentially on February 28, 2020. Cowen, Evercore ISI, Stifel and Mizuho Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
